Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib in Recurrent Epithelial Ovarian Cancer (FAB)
NCT04780945Phase 2Terminated
- Sponsor
- Leiden University Medical Center
- Start
- Jan 2019
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib in epithelial ovarian cancer (EOC), sponsored by Leiden University Medical Center. Started Jan 2019; status: terminated.
02
Drugs
olaparib
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on NCT04780945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04780945.